Quarterly Consolidated Statement Of Cash Flows

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7328356

Concept 2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
As at
2022-03-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
2,724,000,000 JPY
3,916,000,000 JPY
Interest and dividends received
414,000,000 JPY
337,000,000 JPY
Interest paid
-41,000,000 JPY
-51,000,000 JPY
Income taxes paid
-1,611,000,000 JPY
-850,000,000 JPY
Net cash provided by (used in) operating activities
1,486,000,000 JPY
3,351,000,000 JPY
Cash flows from investing activities
Purchase of securities
-500,000,000 JPY
-400,000,000 JPY
Purchase of property, plant and equipment
-1,320,000,000 JPY
-461,000,000 JPY
Proceeds from sale of property, plant and equipment
1,000,000 JPY
0 JPY
Purchase of investment securities
-352,000,000 JPY
JPY
Proceeds from sale of investment securities
4,230,000,000 JPY
190,000,000 JPY
Other, net
845,000,000 JPY
-170,000,000 JPY
Net cash provided by (used in) investing activities
1,706,000,000 JPY
-1,126,000,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-3,138,000,000 JPY
-1,423,000,000 JPY
Dividends paid
-792,000,000 JPY
-452,000,000 JPY
Other, net
-22,000,000 JPY
JPY
Net cash provided by (used in) financing activities
-3,943,000,000 JPY
-1,820,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
-15,000,000 JPY
-2,000,000 JPY
Net increase (decrease) in cash and cash equivalents
-766,000,000 JPY
402,000,000 JPY
Cash and cash equivalents
16,738,000,000 JPY
17,505,000,000 JPY
17,103,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.